On March 8, 2024, dsm-firmenich, a leader in nutrition, health, and beauty innovation, announced the divestiture of its entire stake in DSM Jiangshan Pharmaceutical Co., Ltd. to Jingjiang Cosfocus Health Technology Co., Ltd. The transaction marked the conclusion of a strategic review announced on June 28, 2023, concerning the future of its Vitamin C plant located in Jinjiang, China. While financial specifics of the deal remain undisclosed, this move represents a pivot in dsm-firmenich’s business strategy as it continues to adapt and expand its global operations, which span almost 60 countries and generate revenues exceeding €12 billion. Committed to sustainable solutions with natural and renewable resources, dsm-firmenich maintains a workforce of approximately 30,000 employees worldwide, dedicated to producing essential ingredients across multiple sectors. The impact of this transaction on the Vitamin C market, as well as dsm-firmenich’s broader strategic adjustments, might invite further analysis, especially since the financial terms are not public. Stakeholders and market analysts may interpret this divestiture as an emphasis on dsm-firmenich’s core competencies, potentially signaling additional realignments within their portfolio.
“Chemicals”, “Pharmaceuticals”, “Consumer Goods”,”Switzerland”, “Netherlands”, “China”
https://contentapi.cision.com/api/v1.0/releases/20240308EN55817